Tillkännagivande • Feb 04
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jan 07
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,981,343
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Rights Offering Tillkännagivande • Dec 17
Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Tillkännagivande • Nov 27
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,783,786
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing New Risk • Nov 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-AU$268k). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m (AU$322k revenue, or US$208k). Market cap is less than US$10m (AU$4.84m market cap, or US$3.13m). Minor Risk Significant insider selling over the past 3 months (AU$564k sold). Recent Insider Transactions • Oct 24
Insider recently sold AU$114k worth of stock On the 22nd of October, Saurabh Jain sold around 6m shares on-market at roughly AU$0.02 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$28k more than they bought in the last 12 months. Tillkännagivande • Oct 02
Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025 Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025. Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.008 loss per share (vs AU$0.018 loss in FY 2024) Full year 2025 results: AU$0.008 loss per share (improved from AU$0.018 loss in FY 2024). Net loss: AU$1.45m (loss narrowed 54% from FY 2024). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Jul 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-AU$311k). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (AU$196k revenue, or US$129k). Market cap is less than US$10m (AU$6.58m market cap, or US$4.32m). Tillkännagivande • May 02
Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,000,000
Price\Range: AUD 0.021
Discount Per Security: AUD 0.00126
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,428,572
Price\Range: AUD 0.021
Discount Per Security: AUD 0.00126
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Feb 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-AU$311k). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (AU$4.05m market cap, or US$2.53m). New Risk • Dec 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-AU$90k). Earnings have declined by 5.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m (AU$398k revenue, or US$248k). Market cap is less than US$10m (AU$3.86m market cap, or US$2.40m). Tillkännagivande • Oct 11
Opyl Limited, Annual General Meeting, Nov 21, 2024 Opyl Limited, Annual General Meeting, Nov 21, 2024. Tillkännagivande • Sep 05
Opyl Limited Announces Company Secretary Changes Opyl Limited announced the appointment of Mr. Jonathan Hart as the new Company Secretary, effective immediately. Mr. Hart has 20+ years of corporate advisory experience. He has extensive cross border experience specializing in corporate advisory, scale up and debt and equity financing, across a broad range of industry sectors. Mr. Hart holds a Bachelor of Laws and Commerce and currently serves as a director of Hartness Consulting Pty Ltd, established in 2012 specializing in corporate advisory and equity services to private and publicly listed companies in a range of sectors including technology, healthcare and resources. His extensive experience and deep understanding of corporate governance, compliance, and
strategic advisory will be instrumental as Opyl continues to execute its strategic initiatives. The Board takes this opportunity to thank Mr. David Lilja of DLK Advisory for his invaluable
contributions to the Company as the outgoing Company Secretary. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.018 loss per share (vs AU$0.022 loss in FY 2023) Full year 2024 results: AU$0.018 loss per share. Revenue: AU$932.1k (up 51% from FY 2023). Net loss: AU$3.13m (loss widened 81% from FY 2023). Tillkännagivande • Aug 23
Opyl Limited announced that it has received AUD 0.7 million in funding Opyl Limited announced that it has received AUD 700,000 through short-term loan agreements in funding on August 22, 2024. The transaction includes participation from new lenders Peak Asset Management LLC, Irwin Biotech Nominees Pty Ltd, Rip Opportunities Pty Ltd and Antanas "Tony" Guoga. Tillkännagivande • Apr 30
Opyl Limited, Annual General Meeting, May 27, 2024 Opyl Limited, Annual General Meeting, May 27, 2024, at 15:00 E. Australia Standard Time. Agenda: To consider approval of disposal of OPIN business; to election of executive-director Mr. Saurabh Jain; to approval of issue of shares to Mr. Mark Ziirsen conversion of director fees outstanding; to approval of issue of shares to Mr. Damon Rasheed conversion of director fees outstanding; to approval of issue of shares to Mr. Antanas Guoga conversion of director fees outstanding; to approval to issue of 10,000,000 lead manager options; to ratification of prior issue of 19,200,000 placement shares; to ratification of prior issue of 429,185 shares; and to consider other matters if any. New Risk • Apr 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$64k). Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (AU$572k revenue, or US$375k). Market cap is less than US$10m (AU$4.06m market cap, or US$2.66m). Tillkännagivande • Jan 17
Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million. Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,905,260
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Transaction Features: Rights Offering Tillkännagivande • Nov 24
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer Opyl Limited announced the appointment of Mr. Saurabh Jain as interim Chief Executive Officer of Opyl, effective 24 November 2023. Saurabh is tasked with overseeing and driving the launch of Opyl's new predictive analytics and insights platform, TrialKey, and continuing to support the Opin business as it executes on its new go-to-market strategy. Saurabh is an accomplished technology entrepreneur with a track record of commercialising, scaling and transitioning management to proven leadership in emerging technology businesses. In 1997, he founded Netpro Express, an internet service provider that was later acquired by Telstra. Since then, Saurabh has held various senior executive roles at Ventia, Cushman Wakefield and was previously CEO and Executive Director of Urbanise. Most recently, Saurabh joined the Spacetalk board where he stepped into the role of acting CEO before transitioning to the current leadership, at which point he stepped back into his prior role as Non-Executive Director. Saurabh brings over 25 years of experience across both ASX boards and private companies, leveraging his entrepreneurial and commercial acumen, a history of deep technical expertise and oversight over transformative organisational change. His experience will be critical in accelerating the commercialisation of TrialKey, overseeing the growth of Opin, and driving equity value uplift across the business. Saurabh holds a Bachelor of Engineering (Software Engineering), an Executive Master of Business Administration and a Master of Business Technology from the Australian Graduate School of Management, UNSW. Tillkännagivande • Oct 31
Opyl Limited, Annual General Meeting, Nov 29, 2023 Opyl Limited, Annual General Meeting, Nov 29, 2023, at 15:00 AUS Eastern Standard Time. Location: Engine House, 105 Wellington Street Saint Kilda Victoria Australia Agenda: To receive the Financial Statements, Director's Report and Auditor's Report for the Company for the year ended 30 June 2023; to consider and approve the remuneration report; to consider and approve the election of Director; to consider and approve to issue of incentive options; to consider and approve the conversion of Director fees; to consider and approve to issue loan options; and to consider and approve the 10% placement capacity. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.022 loss per share (vs AU$0.038 loss in FY 2022) Full year 2023 results: AU$0.022 loss per share (improved from AU$0.038 loss in FY 2022). Revenue: AU$1.22m (up 36% from FY 2022). Net loss: AU$1.73m (loss narrowed 17% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. New Risk • Aug 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$886k free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (AU$901k revenue, or US$579k). Market cap is less than US$10m (AU$4.45m market cap, or US$2.86m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). New Risk • Jul 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$886k free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (AU$901k revenue, or US$603k). Market cap is less than US$10m (AU$3.66m market cap, or US$2.45m). Tillkännagivande • May 04
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor Opyl Limited announced that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board. His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of Opin and monetising the TrialKey technology platform. Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including: DrugDev, a leading provider of e-clinical technologies and clinical trial payment services; MediGuard, the largest online medication monitoring service; Health Research Solutions (HRS), a late phase contract research organisation; and MedSeed, a pioneer of hospital and GP decision support software. Dr. Stephenson worked for many years as the founder of Quintiles' global late phase research division (now IQVIA) following the acquisition of HRS, and has considerable experience managing organisations within both a public market and private equity-backed environment. He is also the founder and past Chief Executive Officer of the Induction Healthcare Group PLC. Tillkännagivande • Feb 15
Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director Opyl Limited advised that Dr. Julian Chick has resigned as a Non-Executive Director of the Company, effective immediately as part of a planned transition due to his growing external business commitments. Dr. Chick's efforts over the past few years and his contributions to the growth of the business is much appreciated. Board Change • Jan 04
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Megan Robertson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Megan Robertson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 27
Opyl Limited, Annual General Meeting, Nov 28, 2022 Opyl Limited, Annual General Meeting, Nov 28, 2022, at 10:00 AUS Eastern Standard Time. Location: Engine House, 105 Wellington Street, St Kilda VIC 3182 St Kilda Australia Agenda: To consider FINANCIAL STATEMENTS AND REPORTS; To consider ADOPTION OF THE REMUNERATION REPORT; To consider RE-ELECTION OF DIRECTOR; to consider APPROVAL OF ISSUE OF INCENTIVE OPTIONS ; To consider APPROVAL OF EMPLOYEE SHARE OPTION PLAN; To consider APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY; To consider APPROVAL OF AMENDMENTS TO THE COMPANY'S CONSTITUTION. Tillkännagivande • Oct 21
Opyl Limited Announces ihat its Clinical Trial Prediction and Protocol Design Software Solution, Trialkey Opyl Limited announced that its clinical trial prediction and protocol design software solution, TrialKey, has successfully achieved a key development milestone, reducing bias to improve predictive accuracy in the model, by accurately tracing a random subset of clinical trials reported to global registries through to their outcomes, with 92% accuracy. This is significant as only around 13% of the circa 431,000 clinical trials1 registered on the USgovernment website, ClinicalTrials.gov, have posted their results to the site and no trials are linked over time as they progress between clinical phases. The huge information gap is a major problem for the medical research sector as no one benefits from past learnings and often repeat protocol (trial plan) design mistakes made in previous trials. This information asymmetry contributes to high trial failure rates and the unnecessary waste of time and money on research destined to fail. The scalable TrialKey Software-as-a-Service (SaaS) solution overcomes this issue by using machine learning/AI and natural language processing (NLP) to link trials across multiple global databases and sources, reducing failure bias and thereby improving predictive and protocol design accuracy and value of the software. The completion of the first major development milestone was funded under the federal government's Innovation Connections grant and was done in partnership with RMIT University's School of Computational Sciences. The linking of clinical trial outcomes across phases leading into an accurate software trial design solution will prove to be an invaluable tool for researchers around the world from big pharma to emerging biotech and medtech. With the rising costs of medical research and clinical trials that translates into the higher cost of new drugs and devices, TrialKey aims to reduce failure rates and therefore waste of valuable financial and clinical resources which it is hoped, will deliver more affordable healthcare. Using a sub-set of 17,661 phase 1, 2 and 3 trials sourced from a public registry, the Opyl team, working with Dr Antonio Jimeno Yepes and Prof Karin Vespoor from RMIT University, was able to estimate linkages to future phases for the same trial 45% of the time. For example, it shows that of the 6,847 phase 2 trials conducted, Opyl was able to find 3,800 phase 3 trials that link to a phase 2 study (55%). Reported Earnings • Aug 31
Full year 2022 earnings released: AU$0.038 loss per share (vs AU$0.028 loss in FY 2021) Full year 2022 results: AU$0.038 loss per share (down from AU$0.028 loss in FY 2021). Revenue: AU$1.26m (up 65% from FY 2021). Net loss: AU$2.09m (loss widened 82% from FY 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 28
Opyl Limited Announces the Commencement of Two New Clinical Trial Recruitment Customer Projects Using Opin Opyl Limited announced the commencement of two new clinical trial recruitment customer projects using Opin, building upon a growing customer base and successful recruitment outcomes. The ASPIRING (haemorrhagic stroke) study led by Sir Charles Gairdner Hospital in Perth and the STRONGER (Long COVID) study led by The George Institute in Sydney are both global neurology studies and are two of the largest recruitment projects Opin has undertaken to date. It is expected that the two projects will provide minimum revenues of $0.3m over a 12- month period recruiting a range of participants to local and international sites. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Mark Ziirsen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 29
Full year 2021 earnings released: AU$0.028 loss per share (vs AU$0.025 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$1.24m (up 100% from FY 2020). Net loss: AU$1.14m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 03
Opyl Limited Announces Clinical Trial Recruitment Platform Opin Enters Global Strategic Alliance Opyl Limited announced that its clinical trial patient recruitment platform, Opin, has achieved a number of milestones including securing the first in a series of planned global and local strategic alliances with clinical trial aggregators and gateways. The 2-year Memorandum of Understanding (MOU) with CCRM Australia provides Opin with approved supplier access to CCRM industry consortium companies and research organizations in the regenerative medicine industry globally. CCRM Australia and the global CCRM network supports the development and commercialisation of regenerative medicine-based technologies as well as cell and gene therapies. The regenerative medicine (stem cells) field accounts for approximately 10% of Australia's public medical research capacity with more than 30 companies in Australia developing products with a regenerative medicine focus. The key benefits for Opin/Opyl will be in initially accessing the large Australian sub-sector and then accessing the CCRM Global Network in North America and Europe. Opin is now a featured service partner on three state-based clinical trial portals used by biopharma and medtech companies looking to host trials and studies in Australia. Opin.ai matches motivated patients to clinical trials anywhere in the world. The proprietary platform uses artificial intelligence to search and rank a global database on the platform of more than 58,000 open trials that are searching for clinical trial participants. Opin, through its platforms, works with companies to accelerate clinical studies as well as providing patient insights into clinical trial options across diseases and medical conditions. Poor recruitment is frequently cited as one of the core reasons for clinical trial failure 3. More
than 80% of clinical trials fail to recruit on time and on budget 4, putting at risk hundreds of millions -- if not billions -- of dollars each year through delays in taking products to market or through complete trial failure as well as delaying vital treatments and medication to patients. Tillkännagivande • May 21
Opyl Limited Introduces Opin - Match Patients to Clinical Trials Opyl Limited to introduce Opin www.opin.ai: a patient-led platform giving people the ability to self-select an interest in any clinical trial or research study anywhere in the world. For the first time patients and carers will have the ability to see and self-select to any clinical trial and research study registered to any regulatory authority, that is open and recruiting participants, on a global scale in one website. Opin is the first major platform the company has commercialised as a scalable enterprise model. The platform is free-of-charge for patients to use and will generate revenue in three ways: by charging research organisations conducting trials a fee to unlock matched patient data, charging to have trials featured on the platform and in social media channels, and using the platform sophisticated data search capability to find matched patients registered to the platform waiting for a trial or study opportunity to open up, anywhere in the world. When patients become genuine partners in their healthcare, and have the opportunity and motivation to learn more and actively participate in decision-making, they generally can achieve much better health outcomes. More than 80% of clinical trials fail to recruit on time and on budget 1. Each month of delay caused by recruitment can cost a biopharmaceutical, medtech or research institute tens or even hundreds of millions of dollars. The cost of clinical trial recruitment represents between 25-33% of clinical trial budget, therefore addressing recruitment inefficiencies, as Opin can do, represents one of the most significant ways to reduce financial wastage in the research sector. A key feature of the Opin approach, and one of their competitive advantages, is in leveraging social media and digital channels to create awareness and a door through which patients and carers can open to access the platform. The Opyl team have been experts in using social media and digital marketing strategies to attract and support patient recruitment to studies and trials for over four years. Opin represents the conversion of years of consulting experience into a scalable, global enterprise solution. The Opin platform incorporates some of the novel AI and predictive analytics technology that Opyl has been developing in the background aimed at improving protocol (clinical trial plan) design. Tillkännagivande • Apr 01
Opyl Limited announced that it expects to receive AUD 1.38 million in funding Opyl Limited (ASX:OPL) announced a private placement of 9,200,000 common shares at a price of AUD 0.15 per share for gross proceeds of AUD 1,380,000 on March 30, 2021. The transaction will include participation from by new and existing shareholders. The transaction is expected to be closed on April 6, 2021. Recent Insider Transactions • Jan 19
Executive Director recently bought AU$701k worth of stock On the 18th of January, Damon Rasheed bought around 42k shares on-market at roughly AU$16.57 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$423k more in shares than they have sold in the last 12 months. Tillkännagivande • Sep 21
Opyl Ltd Announces Management Changes Opyl Ltd. announced the appointment of Mr. Mark Ziirsen to the Opyl Board effective from September 21, 2020. Mark will also immediately become the new Opyl chair of the Audit and Risk Committee taking over from Mr. Damon Rasheed who will step into an executive director role leverage his expertise in the Artificial Intelligence space, particularly in relation to the Opyl Clinical Trial Predictor Tool. With the recent priority focus on accelerating the development of the Opyl Clinical Trial Predictor Tool, Damon is taking a more active role in supporting the advancement of technologies within the company, leveraging his expertise in AI. Tillkännagivande • Jun 19
Opyl Limited announced that it expects to receive AUD 0.7388 million in funding Opyl Limited (ASX:OPL) announced that it has received commitments for a placement of up to 7,388,000 common shares at a price of AUD 0.10 per share for gross proceeds of AUD 738,800 on June 19, 2020. The transaction included participation from new and existing investors. The placement was oversubscribed. The transaction is expected to close on June 24, 2020. 
